Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion

Core Insights - Kuros Biosciences has enrolled the first patient in the ASTRA study, a global clinical trial aimed at assessing the safety and performance of MagnetOs compared to autograft in foot and ankle fusion procedures [1][4]. Group 1: Study Overview - The ASTRA study is a prospective, randomized, single-blinded, controlled, multi-center trial that will include sites in the U.S., Australia, New Zealand, Europe, and the Middle East [2]. - Approximately 126 patients undergoing hindfoot or ankle fusions will be enrolled and randomized to receive either MagnetOs or autograft [3]. Group 2: Company Commitment - The ASTRA study is part of Kuros' expanding global extremities strategy, demonstrating the company's commitment to building high-quality clinical evidence across various surgical applications [2]. - The CEO of Kuros Biosciences emphasized that the enrollment of the first patient marks a significant milestone in expanding the clinical reach of MagnetOs [4]. Group 3: Product Information - MagnetOs has shown promising results in previous studies, achieving a fusion rate of 79% compared to 47% for autograft in posterolateral fusions [6]. - MagnetOs utilizes a proprietary technology called NeedleGrip to stimulate bone growth without added cells or growth factors, making it a reliable option for surgeons [6].